Physician profile
Andrew Berchuck
NPI 1154349181
$12,293.28
in general payments reported to CMS, 2019-2025
8 companies · $14.38 in 2025
The $14.38 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.71 · 2021: $14.16 · 2023: $12K · 2024: $118 · 2025: $14.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $156 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,046.00 |
| Food and Beverage | $156.32 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $12,046.00 | 2023 | |
| Aadi Bioscience, INC. | $99.98 | 2024 | |
| Myriad Genetic Laboratories, INC. | $41.96 | 2023 | Mychoice Cdx |
| Merck Sharp & Dohme LLC | $32.47 | 2024-2025 | Keytruda, Lynparza |
| Covidien Lp | $30.61 | 2019 | |
| Genentech USA, INC. | $15.53 | 2019 | |
| Myovant Sciences INC. | $14.16 | 2021 | |
| Amgen INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Berchuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.